---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-026652"
form_type: "8-K"
ticker: "WGRX"
cik: "0002030763"
company_name: "Wellgistics Health, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:07:33.420144+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Wellgistics launches Brenzavvy targeting $16B SGLT-2 inhibitor market

## Summary
- Brenzavvy launch targets 33M type II diabetics in US with out-of-pocket costs above cash price.
- EinsteinRx AI platform alerts pharmacists to patients with Class 1A recommendation for SGLT-2 inhibitors.
- Pharmacist-led provider education model aims to improve patient access and create revenue opportunity for pharmacists.
- Wellgistics network includes 6,500+ independent pharmacies primarily in rural communities.
- SGLT-2 inhibitor market reached $16.8B in 2024; US represents 40.8% of market.

## SEC filing metadata
- accession: 0001493152-25-026652
- form_type: 8-K
- ticker: WGRX
- cik: 0002030763
- company_name: Wellgistics Health, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030763/000149315225026652/0001493152-25-026652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030763/000149315225026652/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-026652
- JSON: https://secwatch.observer/filing/0001493152-25-026652.json
- Plain text: https://secwatch.observer/filing/0001493152-25-026652.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.